Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.

Multiple sclerosis brainstem cerebellar disability outcome early symptomatology prognostic marker

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 17 6 2020
medline: 25 9 2021
entrez: 16 6 2020
Statut: ppublish

Résumé

Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values remain unclear. The aim of this study was to investigate long-term disability outcomes in patients with early cerebellar and brainstem symptoms. This study used data from MSBase registry. Patients with early cerebellar/brainstem presentations were identified as those with cerebellar/brainstem relapse(s) or functional system score ⩾ 2 in the initial 2 years. Early pyramidal presentation was chosen as a comparator. Andersen-Gill models were used to compare cumulative hazards of (1) disability progression events and (2) relapses between patients with and without early cerebellar/brainstem symptoms. Mixed effect models were used to estimate the associations between early cerebellar/brainstem presentations and expanded disability status scale (EDSS) scores. The study cohort consisted of 10,513 eligible patients, including 2723 and 3915 patients with early cerebellar and brainstem symptoms, respectively. Early cerebellar presentation was associated with greater hazard of progression events (HR = 1.37, Early cerebellar presentation is associated with unfavourable outcomes, while early brainstem presentation is associated with favourable prognosis. These presentations may be used as MS prognostic markers and guide therapeutic approach.

Sections du résumé

BACKGROUND
Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values remain unclear.
OBJECTIVE
The aim of this study was to investigate long-term disability outcomes in patients with early cerebellar and brainstem symptoms.
METHODS
This study used data from MSBase registry. Patients with early cerebellar/brainstem presentations were identified as those with cerebellar/brainstem relapse(s) or functional system score ⩾ 2 in the initial 2 years. Early pyramidal presentation was chosen as a comparator. Andersen-Gill models were used to compare cumulative hazards of (1) disability progression events and (2) relapses between patients with and without early cerebellar/brainstem symptoms. Mixed effect models were used to estimate the associations between early cerebellar/brainstem presentations and expanded disability status scale (EDSS) scores.
RESULTS
The study cohort consisted of 10,513 eligible patients, including 2723 and 3915 patients with early cerebellar and brainstem symptoms, respectively. Early cerebellar presentation was associated with greater hazard of progression events (HR = 1.37,
CONCLUSION
Early cerebellar presentation is associated with unfavourable outcomes, while early brainstem presentation is associated with favourable prognosis. These presentations may be used as MS prognostic markers and guide therapeutic approach.

Identifiants

pubmed: 32538713
doi: 10.1177/1352458520926955
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

755-766

Auteurs

Minh Le (M)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Charles Malpas (C)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Sifat Sharmin (S)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Dana Horáková (D)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.

Eva Havrdova (E)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.

Maria Trojano (M)

Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.

Guillermo Izquierdo (G)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Sara Eichau (S)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

Serkan Ozakbas (S)

Dokuz Eylul University, Konak/Izmir, Turkey.

Alessandra Lugaresi (A)

IRCCS Istituto delle Scienze Neurologiche di Bologna, UOSI Riabilitazione Sclerosi Multipla, Bologna, Italy/Dipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.

Alexandre Prat (A)

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, QC, Canada.

Marc Girard (M)

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, QC, Canada.

Pierre Duquette (P)

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, QC, Canada.

Catherine Larochelle (C)

Centre hospitalier de l'Universite de Montreal (CHUM), Montreal, QC, Canada.

Raed Alroughani (R)

Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.

Roberto Bergamaschi (R)

IRCCS Mondino Foundation, Pavia, Italy.

Patrizia Sola (P)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.

Diana Ferraro (D)

Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.

Pierre Grammond (P)

CISSS de Chaudière-Appalache, Levis, QC, Canada.

Francois Grand' Maison (F)

Neuro Rive-Sud, Quebec, QC, Canada.

Murat Terzi (M)

Faculty of Medicine, 19 Mayis University, Samsun, Turkey.

Cavit Boz (C)

Farabi Hospital, KTU Faculty of Medicine, Trabzon, Turkey.

Raymond Hupperts (R)

Zuyderland Ziekenhuis, Sittard, Netherlands.

Helmut Butzkueven (H)

Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Eugenio Pucci (E)

UOC Neurologia, Azienda Sanitaria Unica Regionale Marche-AV3, Macerata, Italy.

Franco Granella (F)

Department of Medicine and Surgery, University of Parma, Parma, Italy.

Vincent Van Pesch (V)

Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Aysun Soysal (A)

Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.

Bassem I Yamout (BI)

Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.

Jeannette Lechner-Scott (J)

School of Medicine and Public Health, The University of Newcastle Australia, Newcastle, NSW, Australia.

Daniele LA Spitaleri (D)

Azienda Ospedaliera di Rilievo Nazionale, San Giuseppe Moscati - Avellino, Avellino, Italy.

Radek Ampapa (R)

Nemocnice Jihlava, Jihlava, Czech Republic.

Recai Turkoglu (R)

Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.

Gerardo Iuliano (G)

Ospedali Riuniti di Salerno, Salerno, Italy.

Cristina Ramo-Tello (C)

Hospital Germans Trias i Pujol, Barcelona, Spain.

Jose Luis Sanchez-Menoyo (JL)

Hospital de Galdakao-Usansolo, Galdakao, Spain.

Youssef Sidhom (Y)

Department of Neurology, Razi Hospital, Manouba, Tunisia.

Riadh Gouider (R)

Department of Neurology, Razi Hospital, Manouba, Tunisia.

Vahid Shaygannejad (V)

Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of.

Julie Prevost (J)

CSSS Saint-Jérôme, Saint-Jerome, QC, Canada.

Ayse Altintas (A)

School of Medicine, Koc University, Istanbul, Turkey.

Yara Dadalti Fragoso (YD)

Universidade Metropolitana de Santos, Santos, Brazil.

Pamela Ann McCombe (PA)

The University of Queensland, Brisbane, QLD, Australia.

Thor Petersen (T)

Kommunehospitalet, Arhus C, Denmark.

Mark Slee (M)

Flinders University, Adelaide, SA, Australia.

Michael H Barnett (MH)

Brain and Mind Centre, The University of Sydney, Camperdown, NSW, Australia.

Steve Vucic (S)

Westmead Hospital, Sydney, NSW, Australia.

Anneke Van Der Walt (A)

Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia.

Tomas Kalincik (T)

CORe, Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Neurology, The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH